Contraindications and Precautions for Combining Phentermine with Mounjaro (Tirzepatide)
Absolute Contraindications to Phentermine
- The American College of Cardiology recommends avoiding phentermine entirely in patients with any history of cardiovascular disease, including coronary artery disease, stroke, arrhythmias, or congestive heart failure, due to lack of long-term cardiovascular outcome trial data 1
- Phentermine is contraindicated in patients with uncontrolled hypertension as it may further elevate blood pressure 1
- Untreated hyperthyroidism is an absolute contraindication due to concerns for arrhythmias and seizures 1
- Phentermine must not be used concurrently with or within 14 days of monoamine oxidase inhibitors (MAOIs) due to risk of hypertensive crisis 1, 3
- Phentermine is contraindicated in patients with a history of drug abuse, as it is a Schedule IV controlled substance with abuse and dependence potential 1
- Phentermine is absolutely contraindicated in pregnancy 1, 3
Additional High-Risk Situations Requiring Caution
- Untreated closed-angle glaucoma is a contraindication to phentermine, particularly when combined with topiramate 2, 3
- Tirzepatide is contraindicated in persons with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 2
Critical Pre-Treatment Screening Algorithm
- Obtain complete cardiovascular history, including remote history of arrhythmias or structural heart disease, before prescribing this combination 1
- Measure baseline blood pressure and heart rate before initiating treatment 3
- Assess thyroid function to exclude hyperthyroidism before starting phentermine 1, 3
- Evaluate renal function (eGFR) before prescribing phentermine 3
Monitoring Requirements When Combining These Medications
- Monitor blood pressure and heart rate at every visit throughout treatment 3, 4
- Monitor for gastrointestinal side effects (nausea, vomiting, diarrhea), which are common with tirzepatide and can lead to dehydration 2
- Monitor renal function, especially if gastrointestinal side effects occur with tirzepatide 2
- Discontinue phentermine if patient has not lost at least 5% of body weight after 12 weeks on maximum dose 3